Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
European journal of haematology - 110(2023), 2 vom: 27. Feb., Seite 222-223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Regidor, Bernard Sean [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.01.2023 Date Revised 23.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.13896 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348809344 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348809344 | ||
| 003 | DE-627 | ||
| 005 | 20231226041132.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.13896 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348809344 | ||
| 035 | |a (NLM)36367357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Regidor, Bernard Sean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2023 | ||
| 500 | |a Date Revised 23.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a anti-CD38 | |
| 650 | 4 | |a daratumumab | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a venetoclax | |
| 650 | 7 | |a ADP-ribosyl Cyclase 1 |2 NLM | |
| 650 | 7 | |a EC 3.2.2.6 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a CD38 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.2.2.5 |2 NLM | |
| 700 | 1 | |a Siddiqi, Dilawer |e verfasserin |4 aut | |
| 700 | 1 | |a Beatty, Bethany Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwater, Marissa-Skye |e verfasserin |4 aut | |
| 700 | 1 | |a Jew, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Bujarski, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Regina |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 110(2023), 2 vom: 27. Feb., Seite 222-223 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2023 |g number:2 |g day:27 |g month:02 |g pages:222-223 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.13896 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2023 |e 2 |b 27 |c 02 |h 222-223 | ||